News Groundbreaking lung cancer approval a big boost for AZ's Imf... AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients.
News AstraZeneca spies an upturn at last in 2018 AstraZeneca (AZ) will see growth in its revenues once again in 2018, after several years of decline caused by blockbuster expiries.
Views & Analysis Interview: AZ's immunotherapy gamble starts to pay off Robert Iannone, AstraZeneca's head of immune-oncology research, on the unpredictable immunotherapy market.
News Medigene axes staff and refocuses its TCR pipeline Medigene slashes staff and delays trials of its lead TCR therapy candidate as it refocuses its pipeline
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends